SecSonar.com

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Gilead Sciences, Inc. (GILD) is a Drug Manufacturers - General company based in US with a market capitalization of $167.4B. Revenue grew 2.4% year-over-year and the company generated $9.5B in free cash flow. This page tracks GILD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 17.6K employees · IPO Jan 22, 1992

Valuation

Valuation & price

$133.12 · as of May 13, 2026 · -14.6% vs 52w high

19.6

P/E ratio

Latest-FY diluted EPS

7.40

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$156$132$108Jul 25Dec 25Jul 26Jul 7, 25$111.78Jul 9, 25$113.24Jul 11, 25$109.64Jul 15, 25$109.06Jul 17, 25$108.80Jul 21, 25$108.28Jul 23, 25$113.56Jul 25, 25$116.20Jul 29, 25$114.23Jul 31, 25$112.29Aug 4, 25$114.51Aug 6, 25$110.28Aug 11, 25$120.47Aug 13, 25$120.14Aug 15, 25$118.37Aug 19, 25$117.98Aug 21, 25$116.14Aug 25, 25$114.15Aug 27, 25$113.92Aug 29, 25$112.97Sep 3, 25$112.99Sep 5, 25$115.05Sep 9, 25$115.76Sep 11, 25$117.86Sep 16, 25$110.86Sep 18, 25$113.62Sep 22, 25$112.49Sep 24, 25$113.67Sep 26, 25$112.10Sep 30, 25$111.00Oct 2, 25$110.56Oct 6, 25$113.58Oct 8, 25$118.25Oct 10, 25$117.18Oct 14, 25$118.48Oct 16, 25$117.85Oct 21, 25$124.08Oct 23, 25$120.74Oct 27, 25$120.47Oct 29, 25$118.50Oct 31, 25$119.79Nov 4, 25$123.00Nov 6, 25$123.40Nov 10, 25$118.15Nov 12, 25$123.40Nov 14, 25$125.02Nov 18, 25$127.18Nov 20, 25$124.99Nov 25, 25$127.12Nov 28, 25$125.84Dec 2, 25$123.91Dec 4, 25$122.62Dec 8, 25$121.19Dec 10, 25$121.34Dec 12, 25$120.40Dec 16, 25$118.78Dec 18, 25$121.47Dec 22, 25$124.16Dec 24, 25$125.67Dec 29, 25$124.91Jan 2, 26$121.60Jan 6, 26$121.36Jan 8, 26$120.67Jan 12, 26$122.60Jan 14, 26$124.07Jan 16, 26$124.91Jan 21, 26$129.11Jan 23, 26$135.93Jan 27, 26$140.97Jan 29, 26$139.55Feb 2, 26$142.89Feb 4, 26$146.23Feb 9, 26$151.68Feb 11, 26$155.80Feb 13, 26$154.98Feb 18, 26$152.74Feb 20, 26$151.40Feb 24, 26$147.64Feb 26, 26$143.77Mar 2, 26$150.03Mar 4, 26$148.22Mar 6, 26$143.93Mar 10, 26$148.56Mar 12, 26$145.21Mar 17, 26$144.40Mar 19, 26$141.11Mar 23, 26$137.34Mar 25, 26$138.26Mar 27, 26$134.25Mar 31, 26$139.37Apr 2, 26$139.71Apr 7, 26$138.80Apr 9, 26$142.09Apr 13, 26$139.03Apr 15, 26$139.77Apr 17, 26$137.64Apr 22, 26$132.90Apr 24, 26$130.40Apr 28, 26$129.26Apr 30, 26$130.84May 4, 26$132.69May 6, 26$136.30May 8, 26$131.33May 12, 26$134.94May 14, 26$132.06May 18, 26$129.67May 20, 26$130.69May 22, 26$134.36May 28, 26$136.22Jun 1, 26$131.10Jun 3, 26$128.99Jun 5, 26$129.16Jun 9, 26$125.50Jun 11, 26$125.87Jun 15, 26$124.30Jun 17, 26$125.45Jun 22, 26$124.87Jun 24, 26$125.16Jun 26, 26$127.88Jul 2, 26$131.27
$108.2252-week range$155.80
Loading valuation history…

Fundamentals

Key fundamentals

$167.4B

Market cap

2.4%

Revenue growth (YoY)

78.8%

Gross margin

$9.5B

Free cash flow (USD)

$14B

Net debt

-0.2%

Share dilution

2/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$30.4BFY 2017$26.1BFY 2018$22.1BFY 2019$22.4BFY 2020$24.7BFY 2021$27.3BFY 2022$27.3BFY 2023$27.1BFY 2024$28.8BFY 2025$29.4B
$30.4B$29.4B

Free cash flow by year

2016 → 2025

FY 2016$16.3BFY 2017$11.3BFY 2018$7.5BFY 2019$8.3BFY 2020$7.5BFY 2021$10.8BFY 2022$8.3BFY 2023$7.4BFY 2024$10.3BFY 2025$9.5B
$16.3B$9.5B

Gross margin by year

2021 → 2025

FY 202175.8%FY 202279.3%FY 202376.0%FY 202478.3%FY 202578.8%
75.8%78.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $376K · 10b5-1 PlanDickinson Andrew D · Chief Financial Officer · $376.2KJun 16, 2026Filing
  • Insider sellInsider Sell $372K · 10b5-1 PlanMercier Johanna · Chief Comm & Corp Aff Officer · $371.8KJun 16, 2026Filing
  • Insider sellInsider Sell $2.0M · 10b5-1 PlanO'Day Daniel Patrick · Director, Chairman & CEO · $2MJun 2, 2026Filing
  • 8-K eventNew Debt IssuanceMay 20, 2026Filing
  • Insider sellInsider Sell $3.7M · 10b5-1 PlanMercier Johanna · Chief Comm & Corp Aff Officer · $3.7MMay 18, 2026Filing
  • Insider sellInsider Sell $397K · 10b5-1 PlanDickinson Andrew D · Chief Financial Officer · $396.8KMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEquity Incentive Plan UpdateMay 4, 2026Filing
  • Insider sellInsider Sell $1.3M · 10b5-1 PlanO'Day Daniel Patrick · Director, Chairman & CEO · $1.3MApr 29, 2026Filing

Questions

Frequently asked questions

What is Gilead Sciences, Inc.'s market cap?

Gilead Sciences, Inc. (GILD) has a market capitalization of $167.4B.

What is GILD's P/E ratio?

GILD trades at a price-to-earnings ratio of 19.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is GILD's price-to-book (P/B) ratio?

GILD trades at 7.40 times book value per share.

Are insiders buying GILD stock?

SEC Form 4 filings show no open-market insider buys at Gilead Sciences, Inc. in the last 90 days (8 sells).

Same arena

Related companies in Drug Manufacturers - General

AMGN

Amgen Inc.

$180.9B

PFE

Pfizer Inc.

$148.6B

SNY

Sanofi

$105.6B

GSK

GSK plc

$101.9B

NVS

Novartis AG

$287.1B

AZN

AstraZeneca PLC

$288.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.